Statements (15)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:monoclonal_antibody
|
| gptkbp:CASNumber |
1092226-57-4
|
| gptkbp:clinicalTrialPhase |
gptkb:systemic_lupus_erythematosus
rheumatoid arthritis development discontinued |
| gptkbp:developedBy |
gptkb:Eli_Lilly_and_Company
|
| https://www.w3.org/2000/01/rdf-schema#label |
tabalumab
|
| gptkbp:intendedUse |
treatment of autoimmune diseases
|
| gptkbp:macromoleculeType |
human monoclonal antibody
|
| gptkbp:routeOfAdministration |
subcutaneous
intravenous |
| gptkbp:target |
B-cell activating factor (BAFF)
|
| gptkbp:UNII |
6QY1D9Y4F1
|
| gptkbp:bfsParent |
gptkb:BAFF
|
| gptkbp:bfsLayer |
7
|